Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
News provided by Eli Lilly and Company Dec 11, 2025, 06:45 ET In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of their body weight at 68 weeks Retatrutide reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function, with more than 1 out of 8 retatrutide-treated patients completely free from knee pain at the end of the trial Seven additional Phase 3 trials evaluating the investigational once-weekly treatment in obesity and type 2 diabetes are expected to complete in 2026 INDIANAPOLIS, Dec
Stephen and Drew Sinatra welcome top nutritionist and New York Times bestselling author, Ann Louise Gittleman, to talk about her latest book, Radical Longevity, and how it aims to redefine the aging process
Log injection sites and timing
Table of Contents Understanding oral GLP-1 therapy Benefits of removing dosing restrictions Ideal patient profiles for first-line use Impact on clinical decision-making FAQs and key takeaways Understanding Oral GLP-1 Therapy in Diabetes Care Oral GLP-1 therapy mimics the action of glucagon-like peptide-1, a hormone that enhances insulin secretion and reduces glucagon release
They differ in sequence, length, and research focus, and each is a separate 99% HPLC, research-use-only reference peptide
